You must subscribe to access archives older
than one year.
Take a free trial of Briefing In Play® now.
Subscribe Here
TERMS OF USE

The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.

Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for use by individuals, as long as the feeds are used for such individual’s personal, non-commercial use. Any other uses, including without limitation the incorporation of advertising into or the placement of advertising associated with or targeted towards the RSS Content, are strictly prohibited. You are required to use the RSS feeds as provided by Briefing.com and you may not edit or modify the text, content or links supplied by Briefing.com. To acquire more extensive licensing rights to Briefing.com content please review this page.

Link to Content Pages:
The RSS service may be used only with those platforms from which a functional link is made available that, when accessed, takes the viewer directly to the display of the full article on the Briefing.com web site. You may not display the RSS content in a manner that does not permit successful linking to, redirection to or delivery of the applicable Briefing.com web site page. You may not insert any intermediate page, “splash” page or any other content between the RSS link and the applicable Briefing.com web site page.

Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS content, and any and all Briefing.com logos and trademarks used in connection with the RSS service. You are required to provide appropriate attribution to the Briefing.com web site in connection with your use of the RSS feeds. If you provide this attribution using a graphic we require you to use the Briefing.com web site logo that we have incorporated into the Briefing.com RSS feed.

Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any or all of the RSS feeds at any time and to require you to cease displaying, distributing or otherwise using any or all of the RSS feeds for any reason including, without limitation, your violation of any provision of these Terms of Use or the terms and conditions of the Briefing.com Reader Agreement. Briefing.com assumes no liability for any of your activities in connection with the RSS feeds or for your use of the RSS feeds in connection with your web site.

Briefing.com
Subscribers Log In
 
  • HOME
  • OUR VIEW
    • Page One
    • The Big Picture
    • Ahead of the Curve
  • ANALYSIS
    • Premium Analysis
    • Story Stocks
  • MARKETS
    • Stock Market Update
    • Bond Market Update
    • Market Internals
    • After Hours Report
    • Weekly Wrap
  • CALENDARS
    • Upgrades/Downgrades
    • Economic
    • Stock Splits
    • IPO
    • Earnings
    • Conference Calls
    • Earnings Guidance
  • EMAILS
    • Edit My Profile
  • LEARNING CENTER
    • About Briefing.com
    • Ask An Analyst
    • Analysis
    • General Concepts
    • Strategies
    • Resources
    • Video
  • COMMUNITY
    • Twitter
    • Facebook
    • LinkedIn
    • YouTube
    • RSS
  • SEARCH
Login | Archive | EmailEmail |
HOME > Analysis >Story Stocks >The Healthcare sector...
Story Stocks® Archive
Last Update: 07-Sep-12 11:00 ET
The Healthcare sector (-0.25%) is trading lower today, underperforming the S&P 500

General Commentary: Thinly traded Palatin Technologies (PTN) is down slightly this morning, on the announcement that its collaboration partner, AstraZeneca (AZN), has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity. A Phase 1 trial of AZD2820 was halted following a serious adverse event. The decision to discontinue development of the compound was made based on investigations and reviews following the incident. Dr. Carl Spana, President and CEO of Palatin, said, "We have multiple classes of collaboration compounds in various stages of preclinical testing and AstraZeneca has informed us that they remain committed to the advancement of collaboration compounds for treatment of obesity." Gainers on news: Rosetta Genomics (ROSG +5.47%) Seeing positive blog mention Questcor Pharmaceuticals (QCOR +3.80%) Seeing positive blog mention.

Decliners on news: Palatin Technologies (PTN -3.13%) Announced that collaboration partner AstraZeneca (AZN) has decided to discontinue further development of AZD2820, a treatment for obesityGainers on earnings: Cooper Companies (COO +8.90%) Beat quarterly EPS by $0.16 ($1.45 vs $1.29 estimate), revenues rose 7.6% yoy to $378.2 mln vs $367.9 mln estimate; sees Q4 EPS of $1.50-1.55 vs $1.53 estimate, Q4 revs of $390-400 mln vs $385.8 mln estimate; sees FY12 EPS of $5.19-5.24 vs $5.05 estimate, FY12 revs of $1.439-1.449 bln vs $1.43 bln estimateDecliners on earnings: Accuray (ARAY -10.79%) Missed quarterly EPS by $0.08 (-$0.20 vs -$0.12 estimate), revenues fell 7.9% yoy to $101.09 mln vs $107.91 mln estimate; sees FY13 revs of $405-425 mln vs $438.82 mln estimate Hyperion Therapeutics (HPTX -2.98%) Reported Q2 EPS loss of $15.26 vs $17.31 in prior year Lannett (LCI -2.97%) Reported Q4 EPS of $0.05 vs $0.04 single estimate, revenues rose 40% yoy to $35.7 mln vs $32.7 mln estimate.

Upgrades/Downgrades: Endologix (ELGX +5.97%) Initiated with an Outperform at BMO Capital Ziopharm Oncology (ZIOP +3.71%) Hearing positive mention at Stansberry Research Sunshine Heart (SSH +2.92%) Initiated with a Buy at Canaccord Genuity, target $11 Wright Medical (WMGI -1.79%) Initiated with a Market Perform at Northland Securities, target $20 Seattle Genetics (SGEN -3.12%) Downgraded to Perform from Outperform at Oppenheimer, target lowered to $27 from $28.

General Commentary: Thinly traded Palatin Technologies (PTN) is down slightly this morning, on the announcement that its collaboration partner,
 
Add this to my Page Alerts.
MARKET PLACE
SPONSORED LINKS
 
  Follow Us On Linkedin  
 
 
LOGIN

CONTACT US
Support
Sitemap
PREMIUM SERVICES
Take a Tour
Compare Services
Custom Tickers
INSTITUTIONAL SALES
ADVERTISING

CONTENT LICENSING

EMAILS & NEWSLETTERS
ABOUT US
Our Experts
Management Team

COMMUNITY
MEDIA
Events
News
Awards
PRIVACY STATEMENT
Reader Agreement
Policies
Disclaimer
Copyright © Briefing.com, Inc. All rights reserved.
Close
You must log in or register to access this area.
Tip of the Day
Virtual Url Page Popup